iSpecimen (ISPC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
17 Nov, 2026Executive summary
Q3 revenue rose 129% YoY to $244,034, while nine-month revenue fell 71% to $551,983 as specimen volume declined; nine-month net loss widened 7% to $5.85M.
Available cash was $5.56M at September 30, 2026, and management reported substantial doubt about continuing as a going concern for one year after issuance.
Financial highlights
Q3 operating loss was $2.20M vs. $2.83M YoY; net loss was $2.21M vs. $2.78M, and basic and diluted EPS was $(1.03) vs. $(19.05), split-adjusted.
Nine-month operating loss was $6.10M vs. $6.29M YoY; net loss was $5.85M vs. $5.49M, and basic and diluted EPS was $(4.49) vs. $(61.54), split-adjusted.
Q3 revenue increased 129% to $244,034; nine-month revenue declined 71% to $551,983, with specimen volume down 61% to 1,977 and average selling price down 24% to ~$279.
Nine-month operating expenses fell 19% to $6.65M; sales and marketing increased 99% to $3.47M, while technology fell 48% to $841,426.
Cash was $5.56M, working capital $870,936, total assets $9.70M, and stockholders’ equity $4.07M at September 30, 2026.
Outlook and guidance
Plans include driving revenue through revenue-enhancement initiatives, reducing and managing expenses, deferring projects and capital expenditures, and eliminating future operating costs; success is not assured.
Commercial priorities include account-based selling, an outbound sales team, closer sales-marketing coordination, and faster quote conversion; next-day quotes had a 44% quote-to-order conversion ratio through Q3 2026.
Management intends to use existing cash for supply-network growth, increased sales and marketing presence, operational scaling, working capital, and general corporate purposes.
Latest events from iSpecimen
- Nevada conversion leads the agenda as Nasdaq equity compliance remains at risk.ISPC
Proxy filing - Stockholders approved a reverse split proposal with a board-set ratio from 1-for-10 to 1-for-100.ISPC
EGM 2026 - Reverse split vote resumes Oct. 30 under a FOR-versus-AGAINST standard.ISPC
Proxy filing - Four proposals cleared preliminary voting; the reverse-split vote stays open through Oct. 30.ISPC
AGM 2026 - Reverse-split vote adjourned to October 30 under a votes-for-must-exceed-against standard.ISPC
Proxy filing - Special Meeting seeks approval for stock issuances, reverse split, and AI asset acquisition.ISPC
Proxy filing - Stockholders will vote on share issuances, a reverse split, and an AI asset acquisition.ISPC
Proxy filing - Revenue fell 83% and net loss widened, raising substantial doubt about going concern status.ISPC
Q2 2026 - Raising up to $5M via best-efforts offering to fund operations, marketing, and platform growth.ISPC
Registration filing